SARS nucleic acids, proteins, antibodies, and uses thereof
Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.
1. An isolated monoclonal antibody, or antigen binding portion thereof, that specifically binds to a SARS-CoV spike glycoprotein polypeptide (an S polypeptide), or fragment thereof, wherein the antibody, or antigen binding portion thereof, cross-competes for binding to the S polypeptide with a reference antibody, or antigen binding fragment thereof, that comprises:
(a) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:13 or SEQ ID NO:149; and
(b) a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:14.
2. A monoclonal antibody, or antigen binding portion thereof, that binds to a SARS-CoV spike glycoprotein polypeptide (an S polypeptide), or fragment thereof, comprising:
(a) a heavy chain variable region CDR1 comprising the amino acid sequence shown in SEQ ID NO:7;
(b) a heavy chain variable region CDR2 comprising the amino acid sequence shown in SEQ ID NO:8;
(c) a heavy chain variable region CDR3 comprising the amino acid sequence shown in SEQ ID NO:9;
(d) a light chain variable region CDR1 comprising the amino acid sequence shown in SEQ ID NO:10;
(e) a light chain variable region CDR2 comprising the amino acid sequence shown in SEQ ID NO:11; and
(f) a light chain variable region CDR3 comprising the amino acid sequence shown in SEQ ID NO:12.
3. A monoclonal antibody, or antigen binding portion thereof, that binds to a SARS-CoV spike glycoprotein polypeptide (an S polypeptide), or fragment thereof, comprising:
(a) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:13, SEQ ID NO:17 or SEQ ID NO:149; and
(b) a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:14.
4. The antibody, or antigen binding fragment thereof, of claim 1 , 2 or 3 , which is a human antibody, or antigen binding fragment thereof.
5. The antibody, or antigen binding fragment thereof, of claim 1 , 2 or 3 , which is a humanized or chimeric antibody, or antigen binding fragment thereof.
6. A composition comprising an antibody, or antigen binding fragment thereof, of claim 1 , 2 or 3 , and a pharmaceutically acceptable carrier.
7. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, of claim 1 , 2 or 3 , linked to a therapeutic agent.
8. An isolated antibody, or antigen binding portion thereof, that binds to an S polypeptide of SARS-CoV, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:149.
9. An isolated antibody, or antigen binding portion thereof, that binds to an S polypeptide of SARS-CoV, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:14.
10. The antibody, or antigen binding fragment thereof, of claim 2 , 8 or 9 which is a human, humanized or chimeric antibody, or antigen binding fragment thereof.
11. An isolated monoclonal antibody, or an antigen binding portion thereof, which binds to an epitope on the S polypeptide of SARS-CoV recognized by the antibody of claim 2 or 3 .
12. The isolated monoclonal antibody, or an antigen binding portion thereof, of claim 11 wherein the antibody, or an antigen binding portion thereof, binds to an epitope on the S polypeptide of SARS-CoV between amino acids 490 and 510.